Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40537 NEUEHEALTH, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4991296 (State or oth ...

NeueHealth (NEUE) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants George Mikan - Vice Chairman, CEO & PresidentJay Matushak - Chief Financial Officer Operator Good morning, and welcome to New Health's First Quarter twenty twenty five Earnings Conference Call. As a reminder, this call is being recorded. Leading the call today are New Health's President and CEO, Mike Mikan and CFO, Jay Matuszak. Before we begin, we want to remind you that this call may contain forward looking statements un ...

NeueHealth (NEUE) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Good morning, and welcome to New Health's First Quarter twenty twenty five Earnings Conference Call. As a reminder, this call is being recorded. Leading the call today are New Health's President and CEO, Mike Mikan and CFO, Jay Matuszak. Before we begin, we want to remind you that this call may contain forward looking statements under U. S. Federal securities laws. These statements are subject to risks and uncertainties that could cau ...

NeueHealth First Quarter 2025 - Earnings Presentation Privileged & Confidential | © 2024 May 8, 2025 Disclaimer Statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies, as well as statements regardin ...

Exhibit 99.1 DORAL, Fla. (May 8, 2025) (BUSINESSWIRE) – NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE: NEUE), the value- driven healthcare company, today reported financial results for its first quarter ended March 31, 2025. "We are starting 2025 in a very strong position, generating substantial growth in the number of consumers we serve and delivering another quarter of Adjusted EBITDA profitability," said Mike Mikan, President and CEO of NeueHealth. "Our value-driven, consumer-centric care model ...

FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NEUEHEALTH, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4991296 (State or other jurisdiction of incorporation or organization) 9250 NW 36th St Suite 420, Doral, FL 33178 (Address of principal executive offices) (Zip Code) Registrant's telepho ...

NeueHealth (NEUE) Q4 2024 Earnings Call March 20, 2025 01:16 PM ET Company Participants Emily Lombardi - AVP - Enterprise StrategyMike Mikan - President & CEOJay Matushak - Chief Financial Officer Operator Good morning and thank you for joining us for the NUHealth Q4 twenty twenty four Earnings Conference Call. My name is Carly and I'll be coordinating the call today. I'd like to hand over to your host, Emily Lombardi. The floor is yours. Emily Lombardi Good morning, and welcome to NU Health's fourth quarte ...

NeueHealth, Inc (NYSE:NEUE) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Emily Lombardi - Assistant Vice President Mike Mikan - President & Chief Executive Officer Jay Matushak - Chief Financial Officer Operator Good morning, and thank you for joining us for the NeueHealth Q4 2024 Earnings Conference Call. My name is Carlin. I'll be coordinating the call today. And I'd like to hand over to your host, Emily Lombardi. The floor is yours. Emily Lombardi Good morning, and welco ...

Consumer Base Growth - In 2024, NeueHealth served 360,000 value-based consumers, an increase from 355,000 in 2023[3] - As of the start of 2025, NeueHealth reported serving 717,000 consumers, marking a 48% increase compared to 2024[5] Financial Performance - Revenue for the fourth quarter of 2024 was $232,638,000, compared to $292,871,000 in the same quarter of 2023, representing a decrease of approximately 20.6%[3] - Total revenue for the year ended December 31, 2024, was $936.657 million, a decrease of 19.3% from $1,160.802 million in 2023[17] - Net income for the fourth quarter of 2024 was $2,523,000, a significant improvement from a net loss of $460,572,000 in the fourth quarter of 2023[3] - Operating loss for the year ended December 31, 2024, was $107.410 million, compared to a loss of $576.996 million in 2023, showing improvement[17] - Net loss attributable to common shareholders for the year ended December 31, 2024, was $186.330 million, a reduction from $1,200.599 million in 2023[17] Revenue Breakdown - Capitated revenue increased to $259.881 million for the year ended December 31, 2024, up 18.3% from $219.774 million in 2023[17] - ACO REACH revenue decreased significantly to $625.339 million in 2024, down 30.3% from $896.504 million in 2023[17] - ACO REACH revenue for Q4 2024 was $154,249,000, down 29.7% from $219,659,000 in Q4 2023[22] - Total segment revenue decreased to $157,072,000 in Q4 2024 from $220,862,000 in Q4 2023, representing a decline of 29%[22] Cost Management - Medical costs for the year ended December 31, 2024, were $742.140 million, a decrease of 25.6% from $996.582 million in 2023[17] - Medical costs for Q4 2024 were $149,926,000, down from $231,095,000 in Q4 2023, a decrease of 35%[22] - Total operating expenses decreased to $153,968,000 in Q4 2024 from $235,494,000 in Q4 2023, a reduction of 34.6%[22] Operational Metrics - Adjusted EBITDA for the fourth quarter of 2024 was $5,482,000, compared to a loss of $10,356,000 in the same quarter of 2023[3] - Adjusted EBITDA for Q4 2024 was $5,482,000, a significant improvement from a loss of $10,356,000 in Q4 2023[26] - Operating income for Q4 2024 was $3,104,000, compared to a loss of $14,632,000 in Q4 2023[22] - The Operating Cost Ratio increased to 31.3% in Q4 2024 from 22.3% in Q4 2023[27] - Adjusted Operating Cost Ratio improved to 18.4% in Q4 2024, up from 11.1% in Q4 2023[27] Strategic Initiatives - The company has established a strong foundation for strategic growth in 2025, focusing on expanding its consumer base in new and existing markets[2] - NeueHealth is pursuing a merger agreement with NH Holdings 2025, Inc., which will make the company a wholly owned subsidiary of Parent[8] - The company aims to enhance its technology and services to support independent providers and medical groups in performance-based arrangements[7] - The company has filed a preliminary proxy statement with the SEC regarding the merger transaction, urging investors to review the relevant documents carefully[9] Cash and Liabilities - Cash and cash equivalents at the end of the period decreased to $185.405 million from $375.280 million at the beginning of the year[19] - Total current liabilities decreased to $710.228 million in 2024, down from $1,391.257 million in 2023[17] - Total assets decreased to $544.383 million in 2024 from $1,225.480 million in 2023[17] - The company reported a net cash used in operating activities of $123.217 million for the year ended December 31, 2024, compared to $2,726.546 million in 2023[19] Transaction Costs - The company incurred $16,122,000 in transaction-related costs in Q4 2024, compared to $4,363,000 in Q4 2023[26]

Core Viewpoint - An investigation has been initiated by Levi & Korsinsky, LLP regarding potential breaches of fiduciary duty by the board of directors of NeueHealth Inc. (NEUE) [1][2] Group 1 - The investigation focuses on whether the NEUE board of directors has violated its fiduciary duties to the company's stockholders [2] - Levi & Korsinsky, LLP is a nationally recognized law firm with expertise in prosecuting securities litigation and has successfully recovered hundreds of millions of dollars for shareholders [3]